Enterprise Value
75.72M
Cash
63.05M
Avg Qtr Burn
-11.52M
Short % of Float
2.91%
Insider Ownership
21.06%
Institutional Own.
79.40%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LP352 (5-HT2c superagonist) Details Dravet syndrome, Epilepsy, Lennox-Gastaut syndrome, Developmental and Epileptic Encephalopathy | Phase 1/2 Data readout | |
LP659 Details Neurological disorder | Phase 1 Data readout |